Filtered By:
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 12509 results found since Jan 2013.

High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents
AbstractThe purpose was to explore the value of high on-treatment platelet reactivity (HTPR) in predicting long-term clinical outcomes for stroke patients. The platelet reactivity was assayed after being treated with either 75  mg clopidogrel or 100 mg aspirin daily with VerifyNow System in stroke patients. HTPR for clopidogrel was defined as PRU ≥ 208, and that for aspirin was defined as ARU ≥ 550. CYP2C19 genotyping was performed using the Sequenom MassARRAY iPLEX platform. The primary endpoint was a compo site of recurrent ischemic stroke, transient ischemic attack, myocardial infarction, or ischemic vascu...
Source: Translational Stroke Research - October 1, 2021 Category: Neurology Source Type: research

Improved Outcomes After Bleeding Stroke For Patients Who Undergo Surgical Procedure
A minimally invasive procedure to remove blood clots in brain tissue after hemorrhagic stroke appears safe and may also reduce long-term disability, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2013. Of the hundreds of thousands of Americans who have intracerebral hemorrhages (ICH) each year, most are severely debilitated, said Daniel Hanley, M.D., lead author and professor of neurology at Johns Hopkins School of Medicine in Baltimore, Md. ICH is the most common type of bleeding stroke...
Source: Health News from Medical News Today - February 11, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Is Intracerebral Hemorrhage a Time-Dependent Phenomenon After Successful Combined Intravenous and Intra-Arterial Therapy? Brief Reports
Conclusions— ORT influences the rate but not the volume of ICH and appears to be a critical predictor of symptomatic hemorrhage after successful combined intravenous and intra-arterial therapy. To minimize the risk of bleeding, revascularization should be achieved within 4.5 hours of stroke onset.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Mosimann, P. J., Sirimarco, G., Meseguer, E., Serfaty, J.-M., Laissy, J.-P., Labreuche, J., Lapergue, B., Gonzalez-Valcarcel, J., Lavallee, P. C., Cabrejo, L., Guidoux, C., Klein, I. F., Olivot, J.-M., Schouman-Claeys, E., Amarenco, P., Mazighi, M. Tags: Acute Stroke Syndromes, Thrombolysis, Other Stroke Treatment - Surgical Brief Reports Source Type: research

Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation Clinical Sciences
Conclusions— Hemorrhagic stroke rates were higher on warfarin in Asians versus non-Asians, despite similar blood pressure, younger age, and lower international normalized ratio values. Hemorrhagic strokes were significantly reduced by DE in both Asians and non-Asians. DE benefits were consistent across Asian and non-Asian subgroups. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
Source: Stroke - June 24, 2013 Category: Neurology Authors: Hori, M., Connolly, S. J., Zhu, J., Liu, L. S., Lau, C.-P., Pais, P., Xavier, D., Kim, S. S., Omar, R., Dans, A. L., Tan, R. S., Chen, J.-H., Tanomsup, S., Watanabe, M., Koyanagi, M., Ezekowitz, M. D., Reilly, P. A., Wallentin, L., Yusuf, S., the RE-LY In Tags: Other anticoagulants, Embolic stroke Clinical Sciences Source Type: research

Thrombocytopenia and In-hospital Mortality Risk among Ischemic Stroke Patients
Background: Thrombocytopenia has been associated with increased mortality in nonstroke conditions. Because its role in acute ischemic stroke is less well understood, we sought to determine whether thrombocytopenia at admission for acute ischemic stroke was associated with in-hospital mortality.Methods: We used data from a retrospective cohort of stroke patients (1998-2003) at 5 U.S. hospitals. Risk factors considered included conditions that can lead to thrombocytopenia (e.g., liver disease), increase bleeding risk (e.g., hemophilia), medications with antiplatelet effects (e.g., aspirin), and known predictors of mortality ...
Source: Journal of Stroke and Cerebrovascular Diseases - September 12, 2012 Category: Neurology Authors: Jason J. Sico, Michael S. Phipps, John Concato, Carolyn K. Wells, Albert C. Lo, Steven E. Nadeau, Linda S. Williams, Aldo J. Peixoto, Mark Gorman, John L. Boice, Dawn M. Bravata Tags: Original Articles Source Type: research

Clopidogrel Use Is Associated With an Increased Prevalence of Cerebral Microbleeds in a Stroke-Free Population: The Rotterdam Study Stroke
Conclusions In stroke-free individuals, clopidogrel use was associated with a higher prevalence and higher number of CMBs. Whether this association is causal requires confirmation in prospective studies, especially given the small number of participants taking clopidogrel and the possibility of residual confounding in this study.
Source: JAHA:Journal of the American Heart Association - September 26, 2013 Category: Cardiology Authors: Darweesh, S. K. L., Leening, M. J. G., Akoudad, S., Loth, D. W., Hofman, A., Arfan Ikram, M., Vernooij, M. W., Stricker, B. H. Tags: Stroke Source Type: research

Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol
Therapeutic hypothermia improves neurological outcome after out‐of‐hospital cardiac arrest or neonatal hypoxic–ischemic injury. Although supported by preclinical evidence, therapeutic hypothermia for acute stroke remains under study. In the Intravascular Cooling in the Treatment of Stroke (ICTuS) trial, awake stroke patients were successfully cooled using an endovascular cooling catheter and a novel antishivering regimen. In the ICTuS‐L study, the combination of endovascular hypothermia and thrombolysis proved feasible; while hypothermia was associated with no increased risk of bleeding complications, there was an ...
Source: International Journal of Stroke - November 10, 2013 Category: Neurology Authors: Patrick D. Lyden, Thomas M. Hemmen, James Grotta, Karen Rapp, Rema Raman Tags: Protocols Source Type: research

Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation Clinical Sciences
Conclusions— In real-world cohort of anticoagulated patients with AF, NT-proBNP provided complementary prognostic information to an established clinical risk score (CHA2DS2–VASc) for the prediction of stroke/systemic embolism. NT-proBNP was also predictive of all-cause mortality, suggesting that this biomarker may potentially be used to refine clinical risk stratification in anticoagulated patients with AF.
Source: Stroke - February 24, 2014 Category: Neurology Authors: Roldan, V., Vilchez, J. A., Manzano-Fernandez, S., Jover, E., Galvez, J., Puche, C. M., Valdes, M., Vicente, V., Lip, G. Y. H., Marin, F. Tags: Arterial thrombosis, Coumarins, Anticoagulants Clinical Sciences Source Type: research

Vitreous Hemorrhage as a Complication of IV-tPA Therapy in a Patient with Acute Stroke (P4.227)
CONCLUSIONS: To our knowledge, this is the first case report of vitreous hemorrhage following acute stroke therapy with IV-tPA. This underscores the risk of intraocular hemorrhage in patients with retinal neovascularization that could occur with other retinal vascular disorders such as diabetic retinopathy. The decision to proceed with IV-tPA in the presence of retinal neovascularization should be made on a case-by-case basis and further discussion with the patient.Disclosure: Dr. Shah has nothing to disclose. Dr. Verstraeten has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Rana has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Shah, L., Verstraeten, T., Wright, D., Rana, S. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Safety of Standard-dose (.9-mg/kg) Alteplase Intravenous Thrombolysis for Acute Ischemic Stroke in Afro–Caribbeans, French West Indies
Conclusions: The excess hemorrhagic risk after standard-dose alteplase infusion into older Afro–Caribbean patients warrants further study to determine the possible role of cerebral microangiopathy and should be evaluated in different black populations.
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Nicolas Chausson, Stéphane Olindo, Julien Joux, Martine Saint-Vil, Mathieu Aveillan, Didier Smadja Tags: Original Articles Source Type: research

Elevated International Normalized Ratio as a Manifestation of Post-thrombolytic Coagulopathy in Acute Ischemic Stroke
Conclusions: We report an under-recognized early transient coagulopathy associated with elevated INR in stroke patients after treatment with tPA.
Source: Journal of Stroke and Cerebrovascular Diseases - July 30, 2014 Category: Neurology Authors: Vivien H. Lee, James J. Conners, Shawna Cutting, Sarah Y. Song, Richard A. Bernstein, Shyam Prabhakaran Tags: Original Articles Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis Clinical Sciences
Conclusions— Our findings suggest that standard-dose NOACs were more effective and safer in Asians than in non-Asians, whereas low-dose NOACs performed similarly in both populations.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Wang, K.-L., Lip, G. Y. H., Lin, S.-J., Chiang, C.-E. Tags: Other anticoagulants, Anticoagulants Clinical Sciences Source Type: research

Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis of Randomized Controlled Trials Original Articles
Conclusions— Novel oral anticoagulants is superior to warfarin for stroke prevention in nonvalvular atrial fibrillation. This benefit was also observed in the elderly population. DEVICE is a reasonable noninferior alternative to warfarin for stroke prevention, but cautious use is essential given safety concerns.
Source: Circulation: Arrhythmia and Electrophysiology - October 20, 2015 Category: Cardiology Authors: Briceno, D. F., Villablanca, P., Cyrille, N., Massera, D., Bader, E., Manheimer, E., Aagaard, P., Ferrick, K., Gross, J., Kim, S. G., Krumerman, A., Palma, E., Guttenplan, N., Romero, J., Fisher, J., Garcia, M., Natale, A., Di Biase, L. Tags: Coumarins, Other anticoagulants, Other Stroke Treatment - Medical Original Articles Source Type: research

Boston Scientific dips on Medicare reimbursement hit for Watchman anti-stroke device
Boston Scientific (NYSE:BSX) shares took a hit yesterday after a Centers for Medicare & Medicaid Services proposal that would limit coverage for the Watchman anti-stroke device. Investors also likely reacted to a pair of Class II recalls from the FDA, sending BSX shares down -4.2% to $18.01 apiece yesterday. Watchman, a transcatheter implant designed to seal off the left atrial appendage to prevent the formation of blood clots that could cause stroke, was approved by the FDA in March and asked for a CMS coverage decision in May. The federal health insurer proposed to limit coverage for Watchman to patients in approv...
Source: Mass Device - November 12, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Implants Cardiovascular Recalls Boston Scientific Cardiac Rhythm Management Stroke Source Type: news

Combining Growth Factor and Bone Marrow Cell Therapy Induces Bleeding and Alters Immune Response After Stroke in Mice Basic Sciences
Conclusions— Our results provide new insights into both BMC-based therapies and immune cell biology and help to understand potential adverse and unexpected side effects.
Source: Stroke - February 22, 2016 Category: Neurology Authors: Strecker, J.-K., Olk, J., Hoppen, M., Gess, B., Diederich, K., Schmidt, A., Schabitz, W.-R., Schilling, M., Minnerup, J. Tags: Animal Models of Human Disease, Basic Science Research, Growth Factors/Cytokines, Inflammation, Treatment Basic Sciences Source Type: research